Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

79
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
79
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

71
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
71
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

119
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
119
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

97
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
97
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

72
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
72
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

76
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
76

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incorporation of Novel Synthetic Glycolipids in Liposomal Nanoparticles Affects Opsonization and In Vivo Clearance.

Angewandte Chemie (International ed. in English)·2026
Same author

Transparent and airtight silica nano- and microchannels with uniform tubular cross-section.

Soft matter·2026
Same author

Requirements for Achieving Self-Healing at Low/Room Temperature in Polymers.

Macromolecules·2026
Same author

Macrophage Phenotype-Dependent Protein Corona Formation Governs Ligand Accessibility and Immune Clearance of Biomimetic Nanoparticles.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

The Distribution of Complement Proteins in Soft and Hard Coronas Impacts Macrophage Uptake of Nanoparticles.

Advanced healthcare materials·2025
Same author

Stable Polyelectrolyte Complexes Releasing Active Agents.

Macromolecular rapid communications·2025

Related Experiment Video

Updated: Mar 15, 2026

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

5.7K

The pro-active payload strategy significantly increases selective release from mesoporous nanocapsules.

Shahed Behzadi1, Mark Steinmann1, Diego Estupiñán1

  • 1Max Planck Institute for Polymer Research, 55128 Mainz, Germany.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|September 5, 2016
PubMed
Summary

A new strategy uses pro-active payloads within mesoporous silica nanocapsules (SiNCs) to prevent premature release. This method ensures selective payload delivery, enhancing applications in drug delivery and self-healing materials.

Keywords:
Pro-active payloadSelective releaseSilica nanocapsuleStimulus-responsiveTriggered release

More Related Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.5K
Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

8.1K

Related Experiment Videos

Last Updated: Mar 15, 2026

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

5.7K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.5K
Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

8.1K

Area of Science:

  • Materials Science
  • Nanotechnology
  • Chemical Engineering

Background:

  • Controlled payload release from mesoporous silica nanocapsules (SiNCs) is crucial for applications like drug delivery.
  • Non-selective release due to the porous silica shell is a significant challenge.
  • Stimulus-responsive shells are key for triggered release mechanisms.

Purpose of the Study:

  • To develop a strategy to prevent premature payload release from SiNCs.
  • To achieve selective payload delivery using a pro-active payload approach.
  • To enhance payload release efficiency using stimulus-responsive silica shells.

Main Methods:

  • Encapsulation of a pro-active payload within SiNCs to prevent premature release.
  • Utilizing the conversion of the pro-active payload to an active molecule for triggered release.
  • Incorporating responsive groups into the silica shell to enhance release.

Main Results:

  • The pro-active payload strategy effectively hindered non-selective release of small payloads.
  • Selective payload release was achieved upon reduction of the encapsulated pro-active payload.
  • Responsive groups in the silica shell significantly enhanced the total amount of released substance.

Conclusions:

  • The pro-active payload strategy is an efficient method to prevent premature release from SiNCs.
  • Selective cargo release can be successfully achieved by combining pro-active payloads with stimulus-responsive materials.
  • This approach holds promise for advanced drug delivery and self-healing material applications.